Fri, Aug 1, 2014, 6:56 PM EDT - U.S. Markets closed

Recent

% | $
Click the to save as a favorite.

Novadaq Technologies Inc. Message Board

hemmerjohn9 400 posts  |  Last Activity: Jul 25, 2014 1:05 PM Member since: Apr 30, 2010
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Good News For Computer Assisted Surgery

    by hemmerjohn9 Jul 23, 2014 12:22 PM
    hemmerjohn9 hemmerjohn9 Jul 25, 2014 1:05 PM Flag

    The tax is not insignificant. A local Medical Device Company here in Central New York cut 10 percent of their work force 275 jobs in the past year because of the Medical Device tax. Anytime the government passes laws that affect an industry the law an it's effects are valid to discuss in an industry message board. If the PPACA is so wonderful why is "the medical-device and health-insurance industries are doing everything within their power to repeal these "harmful" taxes." (source: PHARMA & HEALTHCARE 7/19/201). When the IRS already takes up to 39% on profits and now wants over 2 percent of revenues off-the-top, the taxes become draconian, especially for small medical device startup companies. It dries up risk capital and stifles innovation which is responsible for most of the advances in better, and less expensive, health care.

  • ISRG results are good news for innovation, computer assisted surgery and medical device companies. Innovation is the best way to improve medical outcomes and decrease long term health care cost. It shows the insanity of the Medical Device Tax and another nail in the coffin of the misnamed Patient Protection and Affordable Care Act.

  • Reply to

    Abstral sales high enough to warrant buying Zuplenz

    by kyleao242 Jul 22, 2014 11:09 AM
    hemmerjohn9 hemmerjohn9 Jul 22, 2014 11:20 AM Flag

    My thought was that they can use the same sales team.

  • The Israel's are using robots the check out the Hamas tunnels. I wonder if the are using the SUGV's or other IRobot military robots.

  • Reply to

    why the stock is dropping..........

    by jeslivermore2002 Jul 15, 2014 11:17 AM
    hemmerjohn9 hemmerjohn9 Jul 15, 2014 3:23 PM Flag

    Yellen prints money destroys value through inflation. Biotech's discover better and less expensive ways to treat illnesses which creates real value. She is a dunce.

  • Reply to

    Accuray International opens HQ in Morges

    by pauvrepapillon Jul 12, 2014 3:08 PM
    hemmerjohn9 hemmerjohn9 Jul 14, 2014 11:30 PM Flag

    There is a book "Dying to Get to Oklahoma" by Ash Mackinnon who's wife had to go from Australia to Oklahoma to get CK treatments. The book was written after she died in 2007 as an effort to get the Australian Heath Service (I don't know it's official title) to get a CK in Australia. After all these years it is good to see they got one. Maybe things really are looking up. The book is still available on Amazon.

  • Reply to

    Just Bought 20k at 2.26

    by golongn2014 Jul 10, 2014 9:46 AM
    hemmerjohn9 hemmerjohn9 Jul 11, 2014 2:26 PM Flag

    Please do or provide a link. Thanks.

  • Reply to

    Proton Therapy

    by supremerule Jul 5, 2014 11:21 AM
    hemmerjohn9 hemmerjohn9 Jul 7, 2014 9:41 PM Flag

    I would not worry...

    ASTRO Says Few Cancers Qualify for Proton Therapy
    Published: Jun 4, 2014
    By Charles Bankhead, Staff Writer, MedPage Today

    'Action Points

    Evidence to support reimbursement for proton-beam therapy remains limited to several relatively uncommon cancers, although some patients enrolled in clinical trials also should receive coverage consideration.

    Note that American Society for Radiation Oncology officials found sufficient evidence to support reimbursement for ocular tumors, lesions at or near the base of the skull, primary or metastatic tumors of the spine, hepatocellular carcinoma treated with hypofractionated regimens, primary or benign tumors in children, and patients with genetic syndromes that increase the importance of minimizing total radiation volume.'

  • Reply to

    trxc vs titxf

    by phil_inarizona Jun 28, 2014 10:46 AM
    hemmerjohn9 hemmerjohn9 Jul 2, 2014 4:25 PM Flag

    TRXC will be on market sooner (6-18 months) and a little less expensive. More designed for gall bladder removal and places where cauterizing sufficient to close surgery, e.g. cholecystectomies, etc. TITXF will be more sophisticated will be able to do more repair type surgery. There will be market for both and I own both.

  • Reply to

    Scintillating phantom offers CyberKnife QA

    by hemmerjohn9 Jun 23, 2014 8:05 PM
    hemmerjohn9 hemmerjohn9 Jun 25, 2014 11:56 AM Flag

    Why the thumb down? Do you like to remain ignorant about technology?

  • This is an interesting article for MedicalPhysicsWeb. cut and paste to your browser window.

    http://medicalphysicsweb.org/cws/article/research/57638

  • Reply to

    Is ARAY a takeover target?

    by nuthead48 Jun 16, 2014 10:50 AM
    hemmerjohn9 hemmerjohn9 Jun 16, 2014 6:59 PM Flag

    I could go into a lot of detail why. Often it has to do with not invented here syndrome. Personally, I'm glad they have not. Why dilute superior technology with Inferior products.

  • hemmerjohn9 hemmerjohn9 Jun 14, 2014 10:50 AM Flag

    "Newbies, the THRASHING ADAM FINKLESTEIN rants are all one person"

    What you say certainly is not true. Adam Feuerstein is a political science major who claims he understands the Medical and Bio-pharma fields. His articles are unbalanced, negative, opinionated and mostly untrue. They are ususlly intended to drive the price of a stock down. He did this with ISRG. He has done it to other companies. He continues to do it with GALE even after some well documented articles have prove his comments wrong. This the first time I have commented on him.

  • hemmerjohn9 hemmerjohn9 Jun 5, 2014 8:28 PM Flag

    When ISRG dropped from 357 to 87 all high PE stocks dropped likewise. That had nothing to do with the company but more to do with Hospitals getting financing for capital equipment.

  • Reply to

    Market for Proton Beam Therapy Limited

    by hemmerjohn9 Jun 5, 2014 2:09 PM
    hemmerjohn9 hemmerjohn9 Jun 5, 2014 2:12 PM Flag

    ASTRO Says Few Cancers Qualify for Proton Therapy ...continued'''

    For more common types of cancer -- including lung, prostate, and head and neck -- proton beam therapy should qualify for reimbursement if patients are enrolled in clinical trials or multi-institutional registries.
    The policy reflects ASTRO's goal "to provide balanced, evidence-based guidance to payers that ensures access to proton-beam therapy for cancer patients while being judicious stewards of our nation's and our patients' financial resources," ASTRO board chair Colleen A.F. Lawton, MD, said in a statement.

    In identifying and describing appropriate use of proton-beam therapy, the policy lists four circumstances when use of the technology is reasonable:

    - Target volume is close to a critical structure, requiring a steep dose gradient outside the target to limit the structure's exposure.

    - A decrease in dose inhomogeneity in a large treatment volume is required to avoid an excessive "hotspot" within the target volume.

    -Use of photon-based therapy carries an increased risk of clinically meaningful normal-tissue toxicity.

    - The same area or an adjacent area has been previously irradiated, increasing the need for sculpting to limit the cumulative radiation dose.

  • ASTRO Says Few Cancers Qualify for Proton Therapy
    Published: Jun 4, 2014

    ASTRO Says Few Cancers Qualify for Proton Therapy

    By Charles Bankhead, Staff Writer, MedPage Today

    Action Points

    - Evidence to support reimbursement for proton-beam therapy remains limited to several relatively uncommon cancers, although some patients enrolled in clinical trials also should receive coverage consideration.

    - Note that American Society for Radiation Oncology officials found sufficient evidence to support reimbursement for ocular tumors, lesions at or near the base of the skull, primary or metastatic tumors of the spine, hepatocellular carcinoma treated with hypofractionated regimens, primary or benign tumors in children, and patients with genetic syndromes that increase the importance of minimizing total radiation volume.

    Evidence to support reimbursement fo rproton-beam therapy remains limited to several relatively uncommon cancers, although some patients enrolled in clinical trials also should receive coverage consideration, according to the American Society for Radiation Oncology.

    In developing its "model policy," ASTRO officials found sufficient evidence to support reimbursement for ocular tumors, lesions at or near the base of the skull, primary or metastatic tumors of the spine, hepatocellular carcinoma treated with hypofractionated regimens, primary or benign tumors in children, and patients with genetic syndromes that increase the importance of minimizing total radiation volume.

    ... continued..

  • Reply to

    From Bob Foster's Blog

    by hemmerjohn9 May 27, 2014 11:24 PM
    hemmerjohn9 hemmerjohn9 May 29, 2014 11:59 AM Flag

    Pauve, I totally agree with your assessment. I look for companies with the best technology and like them to be as pure a play as possible. I don't like it when they get acquired diluting the technology. Why dilute the Accuray's precision with Varian's Gantries.

  • hemmerjohn9 by hemmerjohn9 May 27, 2014 11:24 PM Flag

    I had a Conversation with Bob Foster last week. He now works for Anova Cancer Care in Denver. The Following is form his Blog.

    The Coming Paradigm Shift In Prostate Cancer Care
    Conventional thinking is that a single platform, free standing radiation oncology practice is no longer financially viable. I am convinced that is not necessarily so.

    A single platform SRS/SBRT radiation oncology practice can succeed. Anova Cancer Care became a market leader in Denver by partnering with numerous specialty physicians and appropriately educating consumers. Anova, a freestanding practice, treated 320-340 patients in 2013. That's close to maximum throughput capability of its G-4 CyberKnife®. Many hospital based CK programs languish in the 150 to 180 patients-per-year range. Some treat far fewer. It doesn't need to be that way. Change is coming. I am betting my career on it.

    The Paradigm Shift
    Data regarding the long term efficacy of CyberKnife® treatment for early sage prostate cancer will soon reach the ten year tipping point. CyberKnife® is then expected to be acknowledged as the gold standard in early stage prostate cancer care. Anova is in position to take advantage of the coming paradigm shift. What are you prepared to do?
    Be proactive. Let's talk about Next Oncology developing a plan, so you can take advantage of the coming paradigm shift.
    Posted by Bob Foster - Next Oncology's Director of Business Development at 9:47 AM

    Labels: Anova Cancer Care, Bob Foster, CyberKnife, Next Oncology. AERO

  • Reply to

    Stktrader gets it right;again

    by stktrader7 May 15, 2014 4:11 PM
    hemmerjohn9 hemmerjohn9 May 24, 2014 11:56 AM Flag

    You sure talk to yourself a lot.

  • Reply to

    RXI is on Track and Managing its Cash Flow

    by lottawatta2013 May 23, 2014 8:59 AM
    hemmerjohn9 hemmerjohn9 May 24, 2014 11:44 AM Flag

    Ben you have to excuse avi.morax ... his goal is to be the next Adam Feuerstein.

NVDQ
14.76-0.58(-3.78%)Aug 1 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.